Patient Perspective on the Flaura2 Trial

I found this article, Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2 on Tagrisso (osimertinib) Patients & Caregivers Group. It's written by Ivy Elkins.  She's cofounder of the patient advocacy group The EGFR Resisters and a member of the ILCN Editorial Group. All 3 of these groups are excellent resources for cancer education...As is GRACE, of course :). 

I've learned from oncologists mostly through GRACE how important individual choice, balance of quality and quantity of life, communication between onc and patient, and education and advocacy are.  Here is a person living with cancer and raising a family who has written this important commentary about the FLAURA2 trial.